Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Published Online: 2019-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Asim Amin•Benoit Beuselinck•Bernard Escudier•Bohuslav Melichar•Brian I Rini•Bruce Redman•Camillo Porta•Christian K Kollmannsberger•Daniel Y C Heng•David F McDermott•David Pook•Elizabeth R Plimack•Frede Donskov•Hans J Hammers•Howard Gurney•Ignacio Duran•M Brent McHenry•Marc-Oliver Grimm•Michael A Carducci•Michael R Harrison•Nizar M Tannir•Osvaldo Arén Frontera•Pamela Salman•Paul Nathan•Philippe Barthélémy•Raya Leibowitz-Amit•Robert J Motzer•Sabeen Mekan•Saby George•Scott S Tykodi•Sergio Bracarda•Sjoukje F Oosting•Stéphane Oudard•Thomas Powles•Toni K Choueiri•Victoria Neiman•Viktor Grünwald•Yoshihiko Tomita
